Christian Ramers
Internal Medicine · San Diego, CANPI 1730381385
Payments from drug & device makers
Across 898 payments — averaging $751.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$447K
- Viiv Healthcare Company$102K
- AbbVie$100K
- Beckman Coulter, Inc.$11K
- Merck$8K
- Pfizer$3K
- plus $4K from 6 others
What the payments were for
- Consulting fees$167,49025%
- Speaking & faculty fees$413,67261%
- Travel & lodging$74,26911%
- Food & beverage$19,7143%
- Education$480%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 531 | $446,536 |
| Viiv Healthcare Company | 106 | $101,684 |
| AbbVie | 153 | $100,277 |
| Beckman Coulter, Inc. | 1 | $11,000 |
| Merck | 12 | $8,315 |
| Pfizer | 4 | $3,223 |
| Theratechnologies Inc. | 2 | $1,520 |
| GSK | 9 | $1,059 |
| Janssen Products, LP | 1 | $860 |
| Johnson & Johnson(2 entities) | 77 | $630 |
| Biocompatibles, Inc. | 1 | $68 |
| Indivior Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$675,194 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 127 | $495,656 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 23 | $83,968 |
| DovatoDolutegravir Sodium/Lamivudine | 28 | $78,717 |
| JulucaDolutegravir/Rilpivirine | 23 | $76,881 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 20 | $69,024 |
| PrezcobixDarunavir/Cobicistat | 28 | $65,204 |
| VemlidyTenofovir Alafenamide | 39 | $53,532 |
| PifeltroDoravirine | 18 | $29,437 |
| OzempicSemaglutide | 13 | $17,005 |
| LinzessLinaclotide | 12 | $6,168 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $5,893 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,906 |
| Testosterone | 17 | $990 |
| Gabapentin | 86 | $828 |
| Atorvastatin Calcium | 121 | $710 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Vemlidy | $446,536 | $633,156189 claims |
| Viiv Healthcare CompanyDovato, Juluca | $101,684 | $155,59851 claims |
| Johnson & JohnsonPrezcobix | $630 | $65,20428 claims |
| MerckPifeltro | $8,315 | $29,43718 claims |
| AbbVieLinzess | $100,277 | $6,16812 claims |
| GSKBreo Ellipta | $1,059 | $4,90612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.
Other internal medicine in San Diego
- Donald BrandonSan Diego$34M
- Elaine WatkinsSan Diego$11.3M
- James ChenSan Diego$2.9M
- Rita StarrittSan Diego$2.6M
- Hatim HusainSan Diego$2.6M
- Gary FiresteinSan Diego$2.6M
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.